{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
m gemcitabine
to a specific field?
Status:
Possibly Marketed Outside US
Source:
NCT04016376: Phase 4 Interventional Active, not recruiting Breast Cancer
(2019)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Class:
STRUCTURALLY DIVERSE
Status:
Excipient
Class:
G1 SPECIFIED SUBSTANCE
Status:
Other
Class:
G1 SPECIFIED SUBSTANCE
Status:
Other
Class:
G1 SPECIFIED SUBSTANCE
Status:
Other
Class:
G1 SPECIFIED SUBSTANCE
Status:
Other
Class:
G1 SPECIFIED SUBSTANCE
Status:
Other
Class:
G1 SPECIFIED SUBSTANCE